|1.||Pandak, William M: 6 articles (01/2014 - 09/2005)|
|2.||Zhou, Huiping: 6 articles (01/2014 - 09/2005)|
|3.||Hylemon, Phillip B: 6 articles (01/2014 - 09/2005)|
|4.||Yao, Qizhi: 5 articles (08/2012 - 10/2002)|
|5.||Chen, Changyi: 5 articles (08/2012 - 10/2002)|
|6.||Wang, Guangji: 4 articles (01/2014 - 07/2009)|
|7.||Lin, Peter H: 4 articles (11/2011 - 10/2002)|
|8.||Brüning, Ansgar: 4 articles (01/2011 - 02/2009)|
|9.||Dennis, Phillip A: 3 articles (09/2014 - 09/2007)|
|10.||Gurley, Emily C: 3 articles (01/2014 - 07/2009)|
|1.||Acquired Immunodeficiency Syndrome (AIDS)
02/15/2010 - "A highly selective and facile assay of human immunodeficiency virus protease (HIV-PR) has been required for the screening of medicinal inhibitors and also for classifying the subtypes of HIV in the therapeutic treatment of acquired immune deficiency syndrome (AIDS). "
10/15/2003 - "Treatment with drugs designed to inhibit the HIV protease ameliorates immune functions in AIDS patients, reducing cell deletion by apoptosis even in the absence of inhibition of viral spread. "
11/01/2002 - "Of note on this goal, recent studies indicate that the highly active anti-retroviral therapy, including at least one human immunodeficiency virus (HIV) protease inhibitor (PI), is associated with a dramatic decrease in the incidence of AIDS-KS and with a regression of KS in treated individuals. "
07/01/2014 - "Inhibitors of HIV protease are also an essential part of effective HIV/AIDS treatment and have provided great societal benefits. "
03/01/2012 - "An important target for AIDS treatment is the use of HIV protease (PR) inhibitors preventing the replication of the virus. "
|2.||HIV Infections (HIV Infection)
08/01/2005 - "Development of potent inhibitors of HIV protease has revolutionized the treatment of HIV infection. "
05/01/2005 - "Retrospective chart review of patients presenting to the senior author with symptomatic hypertrophic cervicodorsal fat pad attributable to HIV infection and HIV protease inhibitor use. "
10/01/1999 - "Although HIV protease inhibitor therapy partially reverses the lymphoid cell process, this therapeutic approach fails to counter the persistence of HIV infection in myeloid cells. "
01/01/1999 - "At present, treatment of HIV infection uses small inhibitory molecules that target HIV protease; however, the emergence of resistant HIV strains is increasingly problematic. "
12/01/1996 - "HIV-proteinase inhibitors in the management of HIV-infection."
04/25/2003 - "[The HIV protease inhibitor-induced insulin resistance syndrome]."
02/01/2003 - "HIV protease inhibitor treatment is associated with insulin resistance. "
01/01/2003 - "In this review, the cluster of metabolic abnormalities characterised by triglyceride-rich dyslipidaemia and insulin resistance associated with HIV protease inhibitor therapy are considered, along with implications for cardiovascular risk in patients affected by these complications. "
07/07/2000 - "The mechanism of insulin resistance caused by HIV protease inhibitor therapy."
07/01/1999 - "Insulin resistance in HIV protease inhibitor-associated diabetes."
02/20/2015 - "The objective of this study is to determine the epidemiological effectiveness of a first-line antiretroviral regimen with HIV protease inhibitor for preventing recurrent malaria in children under the range of HIV prevalence levels and malaria transmission intensities encountered in sub-Saharan Africa. "
02/20/2015 - "The use of HIV protease inhibitor based regimens as first-line antiretroviral therapy for HIV is an effective measure for reducing recurrent malaria among HIV-infected children in areas where HIV and malaria are coendemic, and artemether-lumefantrine is a first-line antimalarial."
02/20/2015 - "Comparing scenarios of low, intermediate and high newborn HIV prevalence, in a range of malaria transmission settings, our dynamic model predicts that artemether-lumefantrine with HIV protease inhibitor based regimens prevents 0.03-0.10, 5.2-13.0 and 25.5-65.8 annual incidences of malaria per 1000 children, respectively. "
05/01/2015 - "The HIV protease inhibitor, nelfinavir, primarily used for the treatment of HIV infections, has later been shown to be effective in various infectious diseases including malaria. "
01/01/2014 - "Neither the HIV protease inhibitor lopinavir-ritonavir nor the antimicrobial trimethoprim-sulfamethoxazole prevent malaria relapse in plasmodium cynomolgi-infected non-human primates."
|5.||Kidney Neoplasms (Kidney Cancer)
07/01/2012 - "Our previous study showed that the combination of a histone deacetylase (HDAC) inhibitor and an HIV protease inhibitor is effective against renal cancer cells. "
07/01/2012 - "Because HDAC inhibition disrupts the chaperon function of heat shock protein (HSP) 90, we hypothesized that the combination of 17-allylamino-17-demethoxygeldanamycin (17-AAG), an inhibitor of HSP90, and the HIV protease inhibitor ritonavir would also act against renal cancer. "
04/01/2012 - "To investigate the combined effects of the HIV protease inhibitor ritonavir and proteasome inhibitor bortezomib on renal cancer cells. "
|3.||RNA-Directed DNA Polymerase (Reverse Transcriptase)
|4.||Histone Deacetylases (Histone Deacetylase)
|6.||Protease Inhibitors (Protease Inhibitor)
|7.||HIV Reverse Transcriptase
|1.||Highly Active Antiretroviral Therapy (HAART)
|2.||Drug Therapy (Chemotherapy)
|5.||Heterologous Transplantation (Xenotransplantation)